Korea’s LOTTE Biologics expands antibody manufacturing agreement with Ottimo Pharma
May 18, 2026 | Monday | News
Building on the antibody development/manufacturing agreement signed in June last year
South Korea-based LOTTE Biologics has announced an expansion of its collaboration with UK-based Ottimo Pharma, an innovative biotech company developing one-of-a-kind PD-1/VEGFR2 dual-paratopic antibodies, reinforcing a growing strategic partnership.
Building on the antibody development/manufacturing agreement signed in June last year, this continued engagement reflects Ottimo Pharma’s confidence in LOTTE Biologics’ quality, execution, and operational excellence.
This expanded collaboration extends beyond manufacturing, bringing together Ottimo Pharma and LOTTE Biologics to advance Ottimo Pharma’s promising biparatopic antibody, OTP-01, toward launch readiness. Lotte’s development team at the Syracuse Bio Campus in New York, will support commercial process development and characterization activities.
This extended partnership highlights the strength of the relationship and reinforces LOTTE Biologics’ commitment to supporting clients from clinical development through commercialisation.
As a pure-play CDMO, LOTTE Biologics delivers integrated services across development and manufacturing, backed by its dual-site strategy spanning the Syracuse Bio Campus in the US and the Songdo Bio Campus in Korea. This global platform enables consistent quality, operational flexibility, and supply reliability for clients worldwide.